About type 2 diabetes

Type 2 diabetes is a metabolic disorder characterized by hyperglycemia resulting from inadequate insulin secretion or insulin resistance. The most common form of diabetes, it represents 90% of all cases. Often referred to as a pandemic, it is estimated that over 400 million people worldwide are affected by diabetes, with management costs exceeding $800 billion annually.

About DIAMOND therapy

DIAMOND therapy is delivered via an implantable medical device which has the potential to be used as an alternative to insulin.  The safety and efficacy of DIAMOND therapy have been validated in clinical trials involving over 300 patients, including a pilot study which demonstrated a comparable effectiveness to insulin treatment, but avoiding many side-effects and the inconvenience of frequent blood tests and injections.  Designed to treat type 2 diabetes in obese patients who are refractory to oral medication, DIAMOND therapy is delivered via a small pacemaker-like device implanted in the abdomen, which delivers electrical signals to the stomach when eating, improving glycemic control and promoting weight loss.  DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets; it is currently not approved for use in the USA.  For more information, visit www.MetaCure.com/DIAMOND.

About MetaCure

MetaCure, a member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients.  It develops, produces and markets the DIAMOND therapy, an alternative to insulin delivered via a proprietary implantable device.  For more information, visit www.MetaCure.com.

About Hobart Group

The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs.  Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.  Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia.  For more information, visit www.Hobart-Group.com.

References

[1] White JR Jr. A brief history of the development of diabetes medications. Diabetes.
[2] American Diabetes Association (ADA). Standards of care in diabetes—2015. Diabetes Care. 2015;38 Suppl:S4.
[3] Ibid.
[4] Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract. 2010;87:204-10.
[5] Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009;44:1640–1661.
[6] Guillausseau P-J. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes: a survey in general practice. Diabetes Metab. 2003;29:79–81.
[7] Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175-94.
[8] Global Report on Diabetes. World Health Organization, 2016
[9] ADA. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033-46.
[10] Fu H, Curtis BH, Xie W, Festa A, et al. Frequency and causes of hospitalization in older compared to younger adults with type 2 diabetes in the United States: A retrospective, claims-based analysis. J Diabetes Complications. 2014;28:477-81.
[11] IDF. Global diabetes plan: 2011-2021.
[12] Astrup A, Finer N. Redefining type 2 diabetes: ‘Diabesity’ or ‘obesity-dependent diabetes mellitus’? Obes Rev. 2000;1:57-9.